Integrated Shield riders: Fresh focus on cancer drug cover, brace for premium hikes
IP riders now have additional cancer drug benefits far more than the base plans, raising the question of whether current premiums are sustainable
RIDERS to supplement private Integrated Shield Plans (IPs) are set to take on new significance for policyholders, particularly if you are concerned about the extent of cancer drug coverage.
The big question is – are today’s rider premiums sustainable given the riders’ enlarged role in outpatient cancer cover?
Insurers in the IP scheme recently rolled out their base IP plans and riders, with reference to the caps for cancer drug coverage, in line with the cancer drug list (CDL) issued by the health ministry last year.
TRENDING NOW
On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart
Thai and Vietnamese farmers may stop planting rice because of the Iran war. Here’s why
MAS convenes bank CEOs over AI cyberthreats; boards told to own risks, not leave to IT teams
Is it time to scrap COE categories for cars?